ASRGL1: A Potential Drug Target and Biomarker (G80150)

Target Name: ASRGL1

NCBI ID: G80150

ASRGL1

ASRGL1: A Potential Drug Target and Biomarker

ASRGL1 (L-asparaginase) is a protein that is expressed in various tissues of the body, including the brain, muscle, heart, and liver. It is a key enzyme in the 200-carbon asparagine pathway, which is involved in the metabolism of proteins, nucleic acids, and other molecules. ASRGL1 is involved in the breakdown of asparagine, which is a nucleic acid that is found in many proteins, including those that are involved in signaling pathways and cellular processes.

ASRGL1 is a potential drug target for several diseases, including cancer, neurodegenerative diseases, and liver disease. Its involvement in the 200-carbon asparagine pathway has also led to its potential as a biomarker for these conditions.

ASRGL1 is a member of the asparagine synthetase family, which includes enzymes that are involved in the production of asparagine from its precursor amino acid, L-aspartate. Asparagine is a nitrogen-containing compound that is found in many proteins, including those that are involved in signaling pathways and cellular processes. It is involved in the regulation of a wide range of cellular processes, including cell signaling, DNA replication, and protein synthesis.

ASRGL1 is expressed in various tissues of the body, including the brain, muscle, heart, and liver. It is involved in the breakdown of asparagine, which is a amino acid that is found in many proteins, including those that are involved in signaling pathways and cellular processes. ASRGL1 is a key enzyme in the 200-carbon asparagine pathway, which is involved in the metabolism of proteins, nucleic acids, and other molecules.

ASRGL1 is a potential drug target for several diseases, including cancer, neurodegenerative diseases, and liver disease. Its involvement in the 200-carbon asparagine pathway has also led to its potential as a biomarker for these conditions.

One of the challenges in the development of new drugs for these diseases is the difficulty of targeting the underlying causes of the conditions. In the case of ASRGL1, its involvement in the 200-carbon asparagine pathway makes it a potential target for conditions that are characterized by the overuse or underuse of proteins, such as cancer, neurodegenerative diseases, and liver disease.

ASRGL1 is also a potential biomarker for these conditions, as its expression may be increased or decreased in response to the underlying cause. This makes it a promising tool for the development of new diagnostic tests and for the evaluation of therapeutic interventions.

In addition to its potential drug and biomarker applications, ASRGL1 is also of interest as a potential therapeutic target for the treatment of certain diseases. Its involvement in the 200-carbon asparagine pathway has led to its potential as a target for agents that can inhibit the activity of enzymes involved in the production of asparagine, such as inhibitors of the enzyme asparagine synthetase.

Overall, ASRGL1 is a protein that is expressed in various tissues of the body and is involved in the 200-carbon asparagine pathway. Its potential as a drug target and biomarker for several diseases makes it an attractive target for further research and development.

Protein Name: Asparaginase And Isoaspartyl Peptidase 1

Functions: Has both L-asparaginase and beta-aspartyl peptidase activity. May be involved in the production of L-aspartate, which can act as an excitatory neurotransmitter in some brain regions. Is highly active with L-Asp beta-methyl ester. Besides, has catalytic activity toward beta-aspartyl dipeptides and their methyl esters, including beta-L-Asp-L-Phe, beta-L-Asp-L-Phe methyl ester (aspartame), beta-L-Asp-L-Ala, beta-L-Asp-L-Leu and beta-L-Asp-L-Lys. Does not have aspartylglucosaminidase activity and is inactive toward GlcNAc-L-Asn. Likewise, has no activity toward glutamine

The "ASRGL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASRGL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets